Skip to main content
Fig. 4 | BMC Urology

Fig. 4

From: A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

Fig. 4

Median time to discontinuation according to the antimuscarinic used in combination (α-blocker and antimuscarinic, either as FDC or concomitant therapy) (a) and for α-blocker plus solifenacin (FDC vs. concomitant) combination therapy (b). CI: confidence intervals; FDC: fixed-dose combination; HR: hazard ratio; TTD: time to discontinuation

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us